⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14210023 | 0.92 | TYMS (0.58) | — | |
| SCHEMBL21568887 | 0.89 | LPAR3 (0.61) | — | |
| SCHEMBL14437687 | 0.83 | — | — | |
| SCHEMBL744518 | 0.81 | — | — | |
| SCHEMBL4427913 | 0.80 | — | — | |
| SCHEMBL388415 | 0.78 | — | — | |
| SCHEMBL7880658 | 0.78 | TYMS (0.55) | — | |
| Phosphoric Acid SCHEMBL17746596 | 0.78 | EPHX1 (0.55) | — | |
| SCHEMBL11435289 | 0.78 | S1PR2 (0.48) | — | |
| SCHEMBL18251521 | 0.78 | S1PR2 (0.77) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160211-A1 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE, INC. (US) | 2010-06-24 | — | — | US | claimed |
| US-20040063916-A1 | Bactericides; antibiotics | CUMBERLAND PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | claimed |
| JP-2004501161-A | — | — | 2004-01-15 | — | — | JP | claimed |
| US-20030207797-A1 | Glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful | CUMBERLAND PHARMACEUTICALS INC. | 2003-11-06 | — | — | US | claimed |
| US-6635618-B2 | Glycopeptide phosphonate derivatives | THERAVANCE, INC. | 2003-10-21 | — | — | US | claimed |
| EP-1292612-A2 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | Advanced Medicine, Inc. (US) | 2003-03-19 | — | — | EP | claimed |
| US-20020022590-A1 | Useful as antibiotics; reduced tissue accumulation and/or nephrotoxicity when administered to a mammal; useful against vancomycin-resistant microorganisms | CUMBERLAND PHARMACEUTICALS INC. | 2002-02-21 | — | — | US | claimed |
| WO-2001098328-A2 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE, INC. (US) | 2001-12-27 | — | — | WO | claimed |
| US-20220412963-A1 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | WATERS TECHNOLOGIES CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-11353461-B2 | Methods of enhancing MS detection of tagged glycans | WATERS TECHNOLOGIES CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-11061023-B2 | Fluorescence tagging of glycans and other biomolecules through reductive amination for enhanced MS signals | WATERS TECHNOLOGIES CORPORATION (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190331669-A1 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | WATERS TECHNOLOGIES CORPORATION (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190219587-A1 | METHODS OF ENHANCING MS DETECTION OF TAGGED GLYCANS | WATERS TECHNOLOGIES CORPORATION | 2019-07-18 | — | — | US | disclosed |
| US-20160139136-A1 | RAPID FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES WITH ENHANCED MS SIGNALS | WATERS TECHNOLOGIES CORPORATION (US) | 2016-05-19 | — | — | US | disclosed |
| WO-2003018608-A2 | PROCESS FOR PURIFYING GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE, INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| EP-1278549-A2 | CYCLODEXTRIN CONTAINING GLYCOPEPTIDE ANTIBIOTIC COMPOSITIONS | Advanced Medicine, Inc. (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20020077280-A1 | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin | CUMBERLAND PHARMACEUTICALS INC. | 2002-06-20 | — | — | US | disclosed |
| US-20020022590-A1 | Useful as antibiotics; reduced tissue accumulation and/or nephrotoxicity when administered to a mammal; useful against vancomycin-resistant microorganisms | CUMBERLAND PHARMACEUTICALS INC. | 2002-02-21 | — | — | US | disclosed |
| WO-2001098328-A2 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE, INC. (US) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001082971-A2 | CYCLODEXTRIN CONTAINING GLYCOPEPTIDE ANTIBIOTIC COMPOSITIONS | THERAVANCE, INC. (US) | 2001-11-08 | — | — | WO | disclosed |